Investigation of BRAF V600E Mutation in Papillary Thyroid Carcinoma and Tumor-Surrounding Nontumoral Tissues

Abstract

The aim of this study was to investigate the association between the BRAF V600E mutation incidence and histopathologic prognostic risk factors for papillary thyroid carcinoma (PTC) on the Turkish population. The contribution of BRAF V600E mutation in both tumor and tumor-surrounding nontumoral tissues of 108 patients with PTC was assessed using mutant allele-specific amplification-polymerase chain reaction. The BRAF V600E mutation was found in 52.8% of the tumor tissues, and 7.4% of the tumor-surrounding nontumoral tissues. The BRAF V600E mutation was significantly higher in the tumor tissues of the classic variant of PTC (CVPTC) cases than the follicular variant of PTC cases (p=0.001). The presence of the BRAF V600E mutation was more frequent in women, but this gender difference was not statistically significant. BRAF V600E mutation was more frequent in patients with either one of adenomatous hyperplasia or diffuse hyperplasia in tumor-surrounding nontumoral tissues (p=0.012). There was no significant difference in the BRAF V600E mutation distribution among tumor-surrounding nontumoral tissues of the two PTC variants, but it was more frequent in the CVPTC. Recent data suggest that BRAF V600E is an important marker, especially, for CVPTC. We propose that patients who had subtotal thyroid resection might have an increased risk of recurrence at the residual thyroid tissue if they have BRAF V600E mutation in their tumor-surrounding nontumoral tissues.

Occult Langerhans Cell Histiocytosis Presenting with Papillary Thyroid Carcinoma, a Thickened Pituitary Stalk and Diabetes Insipidus

“…One possible mechanism of two identical somatic mutations arising in two different tumors is that BRAF mutations can be found in tumor-surrounding nontumoral tissues. This has specifically been described in PTC [ 13 ] as well as melanomas where BRAF mutations were present in normal skin distant from nevi [ 14 ]. It should be noted that both LCH and PTC were present within the thyroid in our case.…”

Associations of the BRAF (V600E) mutation and p53 protein expression with clinicopathological features of papillary thyroid carcinomas patients

“…Numerous studies have evaluated the association between the BRAF (V600E) mutation, clinicopathological features and clinical outcomes of PTC; however, controversial results have been obtained for a correlation between the BRAF (V600E) mutation and clinicopathological features (1,(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20). Furthermore, multiple previous studies have demonstrated a correlation between the BRAF (V600E) mutation and the high-risk clinicopathological characteristics of PTC, including older age at diagnosis, male gender, large tumor size, the presence of extrathyroidal extension, lymph node and distant metastasis and an advanced stage (9)(10)(11)13,15,16,(18)(19)(20)28,29).…”

“…Numerous studies have investigated potential associations among the BRAF (V600E) mutation, clinicopathological features of PTC and the clinical outcome of patients; however, correlations between the incidence of the BRAF (V600E) mutation and clinicopathological features in PTC patients remains controversial (1,(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20).…”

The Mitochondrial DNA Control Region might have useful Diagnostic and Prognostic Biomarkers for Thyroid Tumors

“…Beside this, thyroid carcinoma was the third most common malignancy in both gender (12%) in Turkey and the second most common malignancy among Turkish women (12%) according to the 2017 Turkish health ministry official cancer report (http://kanser.gov.tr) . In Turkey, the incidence of thyroid carcinoma has increased from 10.8 per 100,000 individuals in 2006 to 20.7 per 100,000 individual in 2014, representing approximately a 2-fold increase (Daglar-Aday et al, 2013).…”